IR

Ismat Rahmani

Active Director Director DIN 08785097
DIN 08785097 First appointment Jul 2020 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2020
Shareholding value •••• Premium profile

About Ismat Rahmani

Data last updated:

Ismat Rahmani is a Director at Doqta Pharma Private Limited (since 2020). The company operates in Chemicals. Doqta Pharma Private Limited reported revenue of ₹2 Lakh (FY 2019).

DIN 08785097
Primary Designation Director
Industry Chemicals
First Appointment 07 Jul 2020
Oldest Company Age 8 yrs
Largest company Doqta Pharma Private Limited · ₹2 Lakh (FY 2019)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Doqta Pharma Private Limited U24234DL2018PTC336330
Director07 Jul 20202018₹2 Lakh (FY 2019)Active

Board colleagues of Ismat Rahmani

NameDINCompanyDesignation
Md Waliullah Rahmani08176157Doqta Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Doqta Pharma Private Limited
Premium access

Shareholding and investment profile for Ismat Rahmani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ismat Rahmani

Ismat Rahmani currently holds 1 directorship: Doqta Pharma Private Limited (Director, since 07 Jul 2020, revenue ₹2 Lakh (FY 2019)).

Ismat Rahmani was first appointed on 07 Jul 2020 as Director at Doqta Pharma Private Limited.

The current boards of Ismat Rahmani's companies include Md Waliullah Rahmani (Doqta Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available